December 17, 2018
Staten Biotechnology B.V. and Novo Nordisk A/S announce collaboration to develop novel treatment for dyslipidaemia
Staten Biotechnology B.V. and Novo Nordisk today announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.
Under the collaboration agreement, Novo Nordisk will provide research and development (R&D) funding and support for Staten to develop its lead asset STT-5058 for treatment of dyslipidaemia.
"Novo Nordisk is joining forces with Staten Biotechnology at an exciting time for us, with the company's lead compound moving towards its first clinical trial, aiming to address the residual cardiovascular risk in patients with hypertriglyceridaemia," said Dr Hilde Steineger, CEO of Staten Biotechnology. "This partnership provides the company not only with a knowledgeable development partner but also with a funding structure that allows founders, management and the founding investors to accelerate the development of company".
"Our partnership with Staten Biotechnology is a key step in executing our strategic priority to expand into cardiovascular diseases. Hypertriglyceridemia is a serious risk factor for cardiovascular disease, in particular often present in people with diabetes and obesity. Staten Biotechnology has developed STT-5058, a new promising concept validated by human genetics, for the treatment of hypertriglyceridemia. Combining Staten's know-how on STT-5058, the scientific excellence of the company's executive team and founders, with Novo Nordisk experience in drug development and commercialization, the project holds potential to make a real difference for people suffering from cardiovascular disease," said Marcus Schindler, Senior Vice President, Global Drug Discovery in Novo Nordisk.
Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its shareholders will potentially receive signing and exercise fees, R&D funding, and milestone payments of up to 430 million euros.
August 21, 2017
Staten Biotechnology announces publication in Nature Medicine of pre-clinical data supporting the therapeutic potential of its antibody STT-5058
in management of dyslipidemia
Staten Biotechnology (“Staten”), a company focused on the treatment of dyslipidemia and reduction of cardiovascular mortality, today announced a publication in Nature Medicine of pre-clinical data, supporting the therapeutic potential of STT-5058 in dyslipidemia management.
March 3, 2017
Staten Biotechnology exercises option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia from argenx N.V.
Staten Biotechnology, a company focused on the treatment of dyslipidemia and reduction of cardiovascular mortality today announced that it has exercised an exclusive option to license ARGX-116 (STT-5058), an anti-ApoC3 SIMPLE Antibody from argenx N.V.